Case Reports in Rheumatology / 2019 / Article / Tab 2

Case Report

A Case of Heparin-Induced Thrombocytopenia That Developed in the Therapeutic Course of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Table 2

Clinical characteristics of previously published four coexisting cases of anti-neutrophil cytoplasmic antibody-associated vasculitis and heparin-induced thrombocytopenia.

SexAgeType of ANCAType of organ injuryTreatmentOnset of HIT and type of heparin

Roe et al. [5]M65PR3Crescentic glomerulonephritis, pulmonary hemorrhagemPSL pulse, PSL, CY, hemodialysis9 days after the start of hemodialysis, unfractionated heparin
Kaneda et al. [6]F91MPOKidney dysfunction, pulmonary hemorrhagemPSL pulse, PSL, hemodialysis13 days after the start of hemodialysis, unfractionated heparin
Mandai et al. [7]M40MPOCrescentic glomerulonephritis, interstitial pneumoniamPSL pulse, PSL, CY, PE, hemodialysis5 days after the start of hemodialysis, unfractionated heparin
Thong et al. [8]M71PR3Kidney dysfunctionmPSL pulse, PSL, CY, hemodialysis15 days after the start of hemodialysis, unfractionated heparin and dalteparin

ANCA, anti-neutrophil cytoplasmic antibody; CY, cyclophosphamide therapy; F, female; HIT, heparin-induced thrombocytopenia; M, male; MPO, myeloperoxidase; mPSL, methylprednisolone; PE, plasma exchange therapy (including double filtration plasmapheresis); PR3, proteinase 3; PSL, prednisolone.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.